The Role of <i>VEGFA, COX2, HUR </i>and <i>CUGBP2</i> in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients
<i>Background and objectives</i>: The effectiveness of neoadjuvant therapy, which is commonly used for stage II-III rectal cancer (RC) treatment, is limited. Genes associated with the pathogenesis of RC could determine response to this treatment. Therefore, the aim of this study was to i...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1010-660X/56/4/192 |
| _version_ | 1797727583957155840 |
|---|---|
| author | Henrikas Pauzas Ugne Gyvyte Tadas Latkauskas Laura Kairevice Paulius Lizdenis Saulius Svagzdys Erika Birgiolaite Irma Kuliaviene Juozas Kupcinskas Algimantas Tamelis |
| author_facet | Henrikas Pauzas Ugne Gyvyte Tadas Latkauskas Laura Kairevice Paulius Lizdenis Saulius Svagzdys Erika Birgiolaite Irma Kuliaviene Juozas Kupcinskas Algimantas Tamelis |
| author_sort | Henrikas Pauzas |
| collection | DOAJ |
| description | <i>Background and objectives</i>: The effectiveness of neoadjuvant therapy, which is commonly used for stage II-III rectal cancer (RC) treatment, is limited. Genes associated with the pathogenesis of RC could determine response to this treatment. Therefore, the aim of this study was to investigate the potential predictive value of <i>VEGFA, COX2, HUR </i>and<i> CUGBP2</i> genes and the associations between post-treatment changes in gene expression and the efficacy of neoadjuvant therapy. <i>Materials and Methods</i>: Biopsies from RC and healthy rectal tissue of 28 RC patients were collected before neoadjuvant therapy and 6-8 weeks after neoadjuvant therapy. The expression levels of VEGFA, COX2, HUR, CUGBP2 genes were evaluated using a quantitative real-time polymerase chain reaction. Results: The results reveal a significantly higher expression of <i>VEGFA</i>, <i>COX2</i> and <i>HUR</i> mRNA in RC tissue compared to healthy rectal tissue (<i>p</i> < 0.05), and elevated <i>VEGFA</i> gene expression in pre-treatment tissues was associated with a better response to neoadjuvant therapy based on T-stage downstaging (<i>p</i> < 0.05). The expression of <i>VEGFA, HUR </i>and<i> </i><i>CUGBP2</i> genes significantly decreased after neoadjuvant therapy (<i>p</i> < 0.05). Responders to treatment demonstrated a significantly stronger decrease of <i>VEGFA</i> and <i>COX2 </i>expression after neoadjuvant therapy than non-responders (<i>p</i> < 0.05). <i>Conclusions</i>: The findings of this study suggest that the pre-treatment <i>VEGFA</i> gene expression might have predictive value for the response to neoadjuvant therapy, while the post-treatment decrease in <i>VEGFA</i> and <i>COX2</i> gene expression could indicate the effectiveness of neoadjuvant therapy in RC patients. |
| first_indexed | 2024-03-12T11:01:47Z |
| format | Article |
| id | doaj.art-c1fe362b57134b6d8720cfb07b988dd5 |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T11:01:47Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-c1fe362b57134b6d8720cfb07b988dd52023-09-02T05:32:38ZengMDPI AGMedicina1010-660X2020-04-015619219210.3390/medicina56040192The Role of <i>VEGFA, COX2, HUR </i>and <i>CUGBP2</i> in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer PatientsHenrikas Pauzas0Ugne Gyvyte1Tadas Latkauskas2Laura Kairevice3Paulius Lizdenis4Saulius Svagzdys5Erika Birgiolaite6Irma Kuliaviene7Juozas Kupcinskas8Algimantas Tamelis9Department of Surgery, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, LithuaniaInstitute for Digestive Research, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, LithuaniaDepartment of Surgery, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, LithuaniaDepartment of Oncology and Hematology, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, LithuaniaDepartment of Surgery, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, LithuaniaDepartment of Surgery, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, LithuaniaDepartment of Surgery, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, LithuaniaDepartment of Gastroenterology, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, LithuaniaInstitute for Digestive Research, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, LithuaniaDepartment of Surgery, Academy of Medicine, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania<i>Background and objectives</i>: The effectiveness of neoadjuvant therapy, which is commonly used for stage II-III rectal cancer (RC) treatment, is limited. Genes associated with the pathogenesis of RC could determine response to this treatment. Therefore, the aim of this study was to investigate the potential predictive value of <i>VEGFA, COX2, HUR </i>and<i> CUGBP2</i> genes and the associations between post-treatment changes in gene expression and the efficacy of neoadjuvant therapy. <i>Materials and Methods</i>: Biopsies from RC and healthy rectal tissue of 28 RC patients were collected before neoadjuvant therapy and 6-8 weeks after neoadjuvant therapy. The expression levels of VEGFA, COX2, HUR, CUGBP2 genes were evaluated using a quantitative real-time polymerase chain reaction. Results: The results reveal a significantly higher expression of <i>VEGFA</i>, <i>COX2</i> and <i>HUR</i> mRNA in RC tissue compared to healthy rectal tissue (<i>p</i> < 0.05), and elevated <i>VEGFA</i> gene expression in pre-treatment tissues was associated with a better response to neoadjuvant therapy based on T-stage downstaging (<i>p</i> < 0.05). The expression of <i>VEGFA, HUR </i>and<i> </i><i>CUGBP2</i> genes significantly decreased after neoadjuvant therapy (<i>p</i> < 0.05). Responders to treatment demonstrated a significantly stronger decrease of <i>VEGFA</i> and <i>COX2 </i>expression after neoadjuvant therapy than non-responders (<i>p</i> < 0.05). <i>Conclusions</i>: The findings of this study suggest that the pre-treatment <i>VEGFA</i> gene expression might have predictive value for the response to neoadjuvant therapy, while the post-treatment decrease in <i>VEGFA</i> and <i>COX2</i> gene expression could indicate the effectiveness of neoadjuvant therapy in RC patients.https://www.mdpi.com/1010-660X/56/4/192rectal cancerneoadjuvant therapyVEGFACOX2HURCUGBP2 |
| spellingShingle | Henrikas Pauzas Ugne Gyvyte Tadas Latkauskas Laura Kairevice Paulius Lizdenis Saulius Svagzdys Erika Birgiolaite Irma Kuliaviene Juozas Kupcinskas Algimantas Tamelis The Role of <i>VEGFA, COX2, HUR </i>and <i>CUGBP2</i> in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients Medicina rectal cancer neoadjuvant therapy VEGFA COX2 HUR CUGBP2 |
| title | The Role of <i>VEGFA, COX2, HUR </i>and <i>CUGBP2</i> in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients |
| title_full | The Role of <i>VEGFA, COX2, HUR </i>and <i>CUGBP2</i> in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients |
| title_fullStr | The Role of <i>VEGFA, COX2, HUR </i>and <i>CUGBP2</i> in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients |
| title_full_unstemmed | The Role of <i>VEGFA, COX2, HUR </i>and <i>CUGBP2</i> in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients |
| title_short | The Role of <i>VEGFA, COX2, HUR </i>and <i>CUGBP2</i> in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients |
| title_sort | role of i vegfa cox2 hur i and i cugbp2 i in predicting the response to neoadjuvant therapy in rectal cancer patients |
| topic | rectal cancer neoadjuvant therapy VEGFA COX2 HUR CUGBP2 |
| url | https://www.mdpi.com/1010-660X/56/4/192 |
| work_keys_str_mv | AT henrikaspauzas theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT ugnegyvyte theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT tadaslatkauskas theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT laurakairevice theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT pauliuslizdenis theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT sauliussvagzdys theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT erikabirgiolaite theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT irmakuliaviene theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT juozaskupcinskas theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT algimantastamelis theroleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT henrikaspauzas roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT ugnegyvyte roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT tadaslatkauskas roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT laurakairevice roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT pauliuslizdenis roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT sauliussvagzdys roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT erikabirgiolaite roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT irmakuliaviene roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT juozaskupcinskas roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients AT algimantastamelis roleofivegfacox2huriandicugbp2iinpredictingtheresponsetoneoadjuvanttherapyinrectalcancerpatients |